Drug intelligence / Profile preview

taragarestrant

Development stage: Phase 3
Lead developer: InventisBio
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Oral

Overview

Taragarestrant (D-0502) is a potent, orally active, and selective estrogen receptor degrader (SERD). It is designed to target and degrade the estrogen receptor (ER), thereby inhibiting ER signaling pathways that drive the growth of ER-positive breast cancer. Taragarestrant has demonstrated strong anti-tumor activity in preclinical models and early-phase clinical trials. The drug is being developed primarily for the treatment of ER-positive, HER2-negative locally advanced or metastatic breast cancer. Clinical studies have shown favorable absorption and safety profiles compared to other oral SERDs[2][4][5][10].

Other names: taragarestranttaragarestrant meglumine

Targets

ESR1 (ERα)

Beyond the preview

Go deeper on taragarestrant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on taragarestrant.

Explore the full profile